MRTX1133 RESISTANCE - AN OVERVIEW

The identification of KRASG12C inhibitors has reignited desire in targeting RAS proteins. This operate describes the invention from the KRASG12D-distinct inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively concentrating on this oncogenic variant.An additional likely benefit of combining KRAS inhibitors and checkpoint inh